Studies examining body composition changes during GLP-1 therapy, including the STEP trials (semaglutide) and SURMOUNT-1 (tirzepatide), have demonstrated that approximately 2540% of total weight lost may come from lean body mass, including skeletal muscle, rather than exclusively from fat mass
Lowering cost to increase uptake Growing competition and the arrival of generic and oral formulations are expected to lower costs significantly, which would widen access to these drugs
In considering bariatric surgery vs GLP-1s, you want to look at your personal goals, and your past experience with weight loss
241 In trials, medication treatments may be more standardized and less influenced by sociocultural variables than lifestyle and surgical interventions
While it's written for four people, this recipe can easily be adjusted to feed more